Talk Title: Proteomics for study of liver diseases
Barbara Sitek, PhD assistant professor is a deputy director of Medical Proteom-Center at the Ruhr University of Bochum, Germany.
B. Sitek studied biology (1995-2000) and made the diploma thesis in the Department of Animal Physiology. The doctorate was performed within the Medical Proteome-Center (2004-2007) in the field of biomarker identification. Since 2007 B. Sitek is a principal investigator of numerous grants from government. In 2010 she was appointed an assistant professorship of proteome research. Her work group Clinical Proteomics deals with the development and application of methods for tackling clinical problems, with an emphasis on the identification of disease-specific biomarkers and therapeutic targets, as well as on the clarification of pathological associations on the protein level. On the one hand, the methods for detecting disease-specific biomarkers in tissue or body fluids are developed. On the other, special attention to the validation of these proteins as biomarkers is devoted.
Intrahepatic cholangiocarcinoma (ICC) and pancreatic ductal adenocarcinoma (PDAC) are highly aggressive cancer types that arise from epithelial cells of the pancreatobiliary system. Owing to their histological similarity, differential diagnosis between ICC and metastases of PDAC located in the liver (mPDAC) frequently proves an unsolvable issue for pathologists. Yet, differential diagnosis of ICC and mPDAC is highly relevant as it leads the patient either to possibly curative resection (for ICC) or to palliation (for mPDAC). Therefore, in this study we were focused in identification of new biomarkers for differential diagnosis.
Moreover we identified MFAP4 as a serum biomarker candidate for hepatic fibrosis and cirrhosis in hepatitis C patients. The aim of the present study was to elucidate the potential of MFAP4 as biomarker for hepatic fibrosis with a focus on the differentiation of no to moderate and severe fibrosis stages and cirrhosis.